Media headlines about Alliqua BioMedical (NASDAQ:ALQA) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alliqua BioMedical earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.6241990219278 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Alliqua BioMedical (ALQA) vs. Its Rivals Critical Analysis (americanbankingnews.com)
- Edited Transcript of ALQA earnings conference call or presentation 9-Nov-17 1:00pm GMT (finance.yahoo.com)
- Investors Recap on Alliqua BioMedical, Inc. (ALQA) with Unusual Volume – Wall Street Morning (wallstreetmorning.com)
- Alliqua BioMedical’s (ALQA) CEO David Johnson on Q3 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Alliqua, Inc. to Host Earnings Call (finance.yahoo.com)
Several equities analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Alliqua BioMedical in a report on Monday, September 18th. Zacks Investment Research raised Alliqua BioMedical from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a report on Tuesday, September 12th. Finally, ValuEngine raised Alliqua BioMedical from a “sell” rating to a “hold” rating in a report on Friday, October 6th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $11.25.
Alliqua BioMedical (NASDAQ:ALQA) opened at $2.04 on Wednesday. Alliqua BioMedical has a 1-year low of $1.99 and a 1-year high of $8.50.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/15/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-alliqua-biomedical-alqa-share-price.html.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.